Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jan 29;10(4):821-828.
doi: 10.7150/jca.27899. eCollection 2019.

KRAS G12V Mutation is an Adverse Prognostic Factor of Chinese Gastric Cancer Patients

Xin-Hui Fu  1   2   3 , Zhi-Ting Chen  1   2   3 , Wen-Hui Wang  4 , Xin-Juan Fan  3 , Yan Huang  3 , Xiao-Bin Wu  5 , Jing-Lin Huang  1   2   3 , Jing-Xuan Wang  1   2   3 , Han-Jie Lin  1   2   3 , Xiao-Li Tan  1   2   3 , Lei Wang  5 , Jian-Ping Wang  1   2
Affiliations

KRAS G12V Mutation is an Adverse Prognostic Factor of Chinese Gastric Cancer Patients

Xin-Hui Fu et al. J Cancer. .

Abstract

This study aims to investigate the molecular characteristics of Chinese gastric cancer patients. In our study, the KRAS, BRAF, and PIK3CA mutation status of 485 GC patients were analyzed by Sanger sequencing. Kaplan-Meier analysis was used to plot survival curves according to different genotypes. The results show that the frequency of KRAS, BRAF and PIK3CA mutations were 4.1%, 1.2% and 3.5%, respectively. BRAF mutations were significantly concentrated in stage III and IV gastric cancer (P=0.009). KRAS G12V mutation carriers have much shorter OS than other mutation carriers and wild-type group patients (P=0.013). In conclusion, only the KRAS G12V mutation has an adverse effect on patient survival.

Keywords: BRAF; Gastric cancer; KRAS; Mutation; PIK3CA.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors have declared that no competing interest exists.

Figures

Figure 1
Figure 1
KRAS G12V is associated with worse patient survival. Kaplan-Meier plots of overall survival (OS) for GC patients by tumor KRAS, BRAF and PIK3CA mutations. (A) KRAS/BRAF/PIK3CA mutation and WT groups. (B) KRAS G13D mutation, (C) KRAS G12S mutation, (D) KRAS G12D mutation, (E) KRAS G12V mutation, (F) PIK3CA exon9 mutation, (G) PIK3CA exon20 mutation, (H) BRAF V600E mutation, other mutation and WT groups.
Figure 2
Figure 2
Tumor location has no effect on the OS of GC patients. Kaplan-Meier plots of overall survival (OS) for GC patients by tumor location (upper group/middle group / lower group and residual or total gastric group).
Figure 3
Figure 3
PIK3CA mutation may be a favorable prognosis marker of the OS of upper, middle and lower GC patients. Kaplan-Meier plots of overall survival (OS) for GC patients by PIK3CA mutation (A) upper GC patients, (B) middle GC patients, (C) lower GC patients.
See this image and copyright information in PMC

References

    1. World Health Organization. GLOBOCAN2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012. http://globocan.iarc.fr/Default.aspx.
    1. Chen W, Zheng R, Zeng H. et al. Annual report on status of cancer in China, 2011. Chin J Cancer Res. 2015;27:2–12. - PMC - PubMed
    1. Arnold M, Karim-Kos HE, Coebergh JW. et al. Recent trends in incidence of five common cancers in 26 European countries since 1988: Analysis of the European Cancer Observatory. Eur. J. Cancer. 2015;51:1164–1187. - PubMed
    1. Uemura N, Okamoto S, Yamamoto S. et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med. 2001;345:784–789. - PubMed
    1. Kim HJ, Karpeh MS. Surgical approaches and outcomes in the treatment of gastric cancer. Semin. Radiat. Oncol. 2002;12:162–169. - PubMed